A breakdown on the decision, and how to navigate these obstacles using a network approach.
IQVIA informs us, new prescriptions for chronic therapies were 20% below what they were before 2020 and telemedicine patient encounters have settled at 10%. Accenture informs us, the low point of in-person pharma rep sales calls over the last year was 35%. These three facts point to lower access to trial medication and give strong impetus for remaking the trial medication adherence space. The CDC informs us that medication non-adherence causes up to 125,000 preventable deaths and $100 billion to 300 billion in preventable medical costs each year. Trial medication is a key solution to medication adherence. Pharmaceutical Commerce asked Hal Walsh, CEO of SymmetryRx, to tell us about the latest digital solutions that truly streamline the route from the manufacturer to the hands of patients in today’s high-tech, low-touch world.
Exploring RCT, RWE and alternative study designs as a path forward
Payers won’t let these products break the bank.
A deep dive into the future of patient service programs and the value of transparency throughout the process.
Various considerations can help pharmaceutical manufacturers and suppliers provide a robust serialization solution based on the FDA's Drug Supply Chain Security Act.
Outlining five network-focused ways industry can support cold chain shipping of advanced therapy products
Gains in temperature-controlled logistics, accelerated by the pandemic, have reshaped the landscape for global pharma distribution
There are a slew of specialist and boutique companies set up to provide high quality services and to meet the changing needs of the pharma industry.
Barcode assessment project demonstrates the ground gained in meeting serialization-readiness requirements for supply chain transparency
How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.
How personalized interventions can help boost the omnichannel experience for patient hubs—and drive engagement and impact adherence in outcomes.
The packaging and shipping of dangerous goods (DG) adds further challenges to the distribution pressures brought about by the pandemic
Product commercialization in Canada is by no means simple, but the end result presents its advantages
Why having these strategies for results—amid disruptions—will be critical to success.
Questions and considerations for pharmaceutical companies in designing and executing strategies to curb the incidence of fake drugs.
When identifying a third-party service provider for ground transport of pharmaceutical freight, it is essential that the shipper partner with a company equipped with the expertise and technologies to plan for and monitor necessary shipments as well as respond to issues that may compromise the freight along its journey.
The top criteria to consider when evaluating and choosing the right airfreight container that can efficiently protect pharma’s cold chain
Although AI has simplified various market access processes, this technology does also present its share of barriers, so what can be done to find a happy medium?
How to best plan out and implement a marketing data hub as a key tool to harnessing today’s omnichannel transformation in pharma
From research and development to the clinical trials phase, pre-conditioning gel packs and PCMs prior to transport, Polar Leasing temperature-controlled chamber rentals are the perfect on-site solution for temporary refrigeration anywhere throughout the cold chain. Learn about our -30C Walk-In Freezer and its features now.
Five strategies to help pharma companies improve their return on investment from adherence-promoting initiatives and drive positive health outcomes for patients
With the standard constantly evolving across the pharma sector, the latest version can help bring benefits to the regulatory process.
Industrialized collaboration is critical to taking next-generation cell and gene therapies to the next level—if companies can build on pandemic-partnering momentum
What does digital innovation actually mean and how is it changing the way that pharma is interacting with HCPs and patients?